USD10
ALLO Shares
About Allogene TherapeuticsAllogene Therapeutics Inc is a clinical stage immuno-oncology company pioneering the development of genetically engineered allogeneic T cell product candidates for the treatment of cancer and autoimmune diseases. Its pipeline includes "off-the-shelf" T cell candidates designed to target cancer cells or eliminate autoreactive cells in patients with autoimmune disorders. Its three core programs are: Large B-Cell Lymphoma (LBCL), Autoimmune Disease (AID) and Renal Cell Carcinoma (RCC).
USD10
ALLO Shares
About Allogene TherapeuticsAllogene Therapeutics Inc is a clinical stage immuno-oncology company pioneering the development of genetically engineered allogeneic T cell product candidates for the treatment of cancer and autoimmune diseases. Its pipeline includes "off-the-shelf" T cell candidates designed to target cancer cells or eliminate autoreactive cells in patients with autoimmune disorders. Its three core programs are: Large B-Cell Lymphoma (LBCL), Autoimmune Disease (AID) and Renal Cell Carcinoma (RCC).
Stats
TRADING WINDOW
Open
CLOSES AT
8:00 PM GMT+0
MARKET CAP
$670.25M
OPEN PRICE
$1.97
LOW (1Y)
$1.04
HIGH (1Y)
$4.46
LOW (24H)
$1.92
HIGH (24H)
$2.04
VOLUME (24H)
$1.92M
55.57%
Price history
Time | Price | Change |
|---|---|---|
Today | $1.97 | |
1 Day | $1.96 | |
1 Week | $2.06 | |
1 Month | $1.88 | |
1 Year | $1.12 |
Past performance is not a reliable indicator of future results.
Legal
Information is provided for informational purposes only, and is not investment advice. This is not an invitation, inducement or recommendation to buy any particular asset, or to employ any particular investment strategy. Coinbase makes no representation as to the accuracy, suitability or validity of any information provided.All ticker names are trademarks of their respective holders. Any ticker reference does not imply affiliate with or endorsement by a third-party. Real-time prices are sourced from third parties, but not from all markets. Source: Nasdaq Last Sale. Morningstar data ©2026.